What is Scienture Holdings, Inc's earnings per share (EPS)?

Scienture Holdings, Inc (SCNX) reported diluted earnings per share of -$2.70 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Scienture Holdings, Inc (SCNX) Financials

SCNX

FY2025 annual

Revenue $432K +215.9% YoY

Net Income -$41.5M -557.9% YoY

EPS (Diluted) -$2.70 YoY not available

Operating Cash Flow -$13.4M +6.2% YoY

Market Cap $15.2M as of Sep 3, 2026

Price / Sales 35.2x on $432K revenue, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 0.2x on $64.1M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SCNX SEC filings page.

Scienture Holdings, Inc (SCNX) reported $432K in revenue for fiscal year 2025, up 215.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SCNX FY2025 2026-08-29

Scienture’s dominant mechanic is heavy operating investment: gross-margin improvement has not yet overcome losses and cash consumption.

FY2024’s positive net income of $9.1M coexisted with operating cash flow of -$14.3M, so reported earnings were not cash earnings from core operations. The following year returned to a net loss of -$41.5M while operating cash flow remained negative at -$13.4M, reinforcing that profitability is not yet the operating engine.

FY2025 research and development spending was $2.0M against revenue of $432K, making development investment several times larger than the reported sales base. Gross margin nevertheless rose from 4.4% in FY2024 to 76.8% in FY2025, but the operating loss reached -$42.6M; better product-level economics have not translated into operating leverage.

Liabilities were $14.1M against equity of $70.1M, indicating equity—not creditors—was the principal reported funding base. The current ratio was 2.9x, and the reported liquidity comparison equaled six months of FY2025 operating outflow, showing improved near-term coverage without implying operating self-sufficiency.

Financial Health Signals

Financial health score not available

Scienture Holdings, Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-2.28

Scienture Holdings, Inc scores -2.28, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($15.2M) relative to total liabilities ($14.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

Scienture Holdings, Inc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Scienture Holdings, Inc reported a net loss of $41.5M while operations used $13.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Scienture Holdings, Inc reported an operating loss of $42.6M against $4.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$344K

QoQ+510.1%

Scienture Holdings, Inc generated $344K in revenue in Q2 2026. Against the prior quarter it is up 510.1%.

EBITDA

-$2.2M

YoY+56.6%

QoQ+26.7%

Scienture Holdings, Inc's EBITDA was -$2.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 56.6% from the same quarter a year earlier. Against the prior quarter it is up 26.7%.

Net Income

-$2.8M

YoY+58.0%

QoQ+17.0%

Scienture Holdings, Inc reported -$2.8M in net income in Q2 2026. This represents an increase of 58.0% from the same quarter a year earlier. Against the prior quarter it is up 17.0%.

EPS (Diluted)

-$0.07

QoQ+12.5%

Scienture Holdings, Inc earned -$0.07 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 12.5%.

Cash & Balance Sheet

Cash & Debt

$8.2M

YoY+53100.8%

QoQ+131.1%

5Y CAGR+12.6%

10Y CAGR+38.3%

Scienture Holdings, Inc held $8.2M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

41M

QoQ+1.1%

5Y CAGR+38.1%

10Y CAGR+2.7%

Scienture Holdings, Inc had 41M shares outstanding in Q2 2026. Against the prior quarter it is up 1.1%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

97.7%

QoQ+2.1pp

Scienture Holdings, Inc's gross margin was 97.7% in Q2 2026, indicating the percentage of revenue retained after direct costs. Against the prior quarter it is up 2.1 percentage points.

Return on Equity

-4.4%

YoY+4.2pp

QoQ+0.7pp

Scienture Holdings, Inc's ROE was -4.4% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 4.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.7 percentage points.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$1.2M

YoY+38.3%

QoQ+46.9%

Scienture Holdings, Inc invested $1.2M in research and development in Q2 2026. This represents an increase of 38.3% from the same quarter a year earlier. Against the prior quarter it is up 46.9%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

SCNX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SCNX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Revenue	N/A	$432K+215.9%	$137K-90.0%	$1.4M-86.7%	$10.3M+3.6%	$9.9M-42.2%	$17.1M+130.3%	$7.4M+94.1%	$3.8M+30.7%	$2.9M+18.1%	$2.5M-14.8%	$2.9M+94.7%	$1.5M+56.5%	$956K
Cost of Revenue	N/A	$100K-23.4%	$131K-90.1%	$1.3M-72.2%	$4.7M-8.0%	$5.1M-54.9%	$11.4M+345.0%	$2.6M+471.3%	$449K	N/A	$16K-91.4%	$190K-56.9%	$440K-53.4%	$944K
Gross Profit	N/A	$331K+5420.1%	$6K-87.8%	$49K-99.1%	$5.5M+16.3%	$4.7M-16.8%	$5.7M+17.2%	$4.9M+44.0%	$3.4M+15.4%	$2.9M+18.1%	$2.5M-8.8%	$2.7M+157.8%	$1.1M+8842.3%	$12K
R&D Expenses	N/A	$2.0M-12.5%	$2.2M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	$7.9M+18.7%	$6.7M+399.6%	$1.3M-20.9%	$1.7M-10.9%	$1.9M-74.7%	$7.5M+71.1%	$4.4M+26.1%	$3.5M+36.8%	$2.5M-27.3%	$3.5M+22.0%	$2.9M+15.0%	$2.5M+18.7%	$2.1M
Operating Income	N/A	-$42.6M-189.7%	-$14.7M-234.4%	-$4.4M-50.8%	-$2.9M+44.9%	-$5.3M-111.1%	-$2.5M-2101.7%	$125K+242.9%	-$88K-122.2%	$395K+139.2%	-$1.0M-634.9%	-$137K+90.4%	-$1.4M+31.3%	-$2.1M
EBITDA	N/A	-$42.1M-186.4%	-$14.7M-312.6%	-$3.6M-24.6%	-$2.9M+45.9%	-$5.3M-111.3%	-$2.5M-2020.7%	$130K	N/A	$408K+140.5%	-$1.0M-655.8%	-$133K+90.7%	-$1.4M+31.4%	-$2.1M
Interest Expense	N/A	$4.1M+205.7%	$1.3M+11.5%	$1.2M+256.4%	$336K+1325.2%	$24K-19.7%	$29K-44.8%	$53K-7.5%	$58K-63.4%	$157K+3.7%	$152K+26.8%	$120K+2777.0%	$4K-42.9%	$7K
Income Tax	N/A	-$2.0M-273.3%	-$534K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$41.5M-557.9%	$9.1M+150.8%	-$17.8M-413.9%	-$3.5M+34.7%	-$5.3M-109.6%	-$2.5M-791.6%	-$284K-3247.0%	$9K-96.9%	$289K+110.5%	-$2.8M-147.1%	-$1.1M+44.5%	-$2.0M+3.8%	-$2.1M
EPS (Basic)	N/A	-$2.70-200.4%	$2.69+111.5%	-$23.35-279.7%	-$6.15-846.2%	-$0.65	N/A	-$0.05	$0.00-100.0%	$0.01+111.1%	-$0.09-125.0%	-$0.04+42.9%	-$0.07+53.3%	-$0.15
EPS (Diluted)	-$2.10	-$2.70	$2.48	-$23.35-280.9%	-$6.13	-$0.65	N/A	-$0.05	$0.00-100.0%	$0.01+111.1%	-$0.09-125.0%	-$0.04+42.9%	-$0.07	-$0.15
Diluted Shares (Avg)	N/A	15M	4M	2M+320.3%	566,609	N/A	N/A	6M	6M-82.9%	34M+8.1%	32M+0.7%	31M+5.0%	30M	14M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$344K	$56K+449.1%	N/A	$590K+809.7%	N/A	$10K	N/A	$65K-83.5%
Cost of Revenue	$8K	$2K-74.2%	N/A	$15K-74.7%	N/A	$10K	N/A	$61K-82.7%
Gross Profit	$336K	$54K+7901.5%	N/A	$575K+14698.4%	N/A	$673	N/A	$4K-90.2%
R&D Expenses	$1.2M+38.3%	$794K+38.2%	N/A	$169K-86.5%	$844K	$575K	N/A	$1.3M
SG&A Expenses	$369K-87.4%	$1.1M-20.7%	N/A	$2.2M+1184.0%	$2.9M+604.8%	$1.4M-71.2%	N/A	$169K+152.2%
Operating Income	-$2.7M+47.7%	-$3.5M+1.7%	N/A	-$4.4M-24.7%	-$5.2M-244.9%	-$3.6M+35.0%	N/A	-$3.5M-359.2%
EBITDA	-$2.2M+56.6%	-$3.1M+14.4%	N/A	-$4.4M-24.7%	-$5.2M-244.9%	-$3.6M+35.0%	N/A	-$3.5M-360.8%
Interest Expense	$270K-58.7%	$37K-94.5%	N/A	$1.8M+729.4%	$653K+13104.5%	$671K+580.9%	N/A	$217K-13.6%
Net Income	-$2.8M+58.0%	-$3.4M-11.0%	N/A	-$3.6M-13.3%	-$6.7M-266.5%	-$3.1M-114.4%	N/A	-$3.2M+9.7%
EPS (Basic)	-$0.07+85.4%	-$0.08+75.8%	-$1.76+76.2%	-$0.19+85.8%	-$0.48+63.1%	-$0.33-101.6%	-$7.38+49.8%	-$1.34+70.7%
EPS (Diluted)	-$0.07	-$0.08	-$1.76	-$0.19	-$0.48	-$0.33	-$6.11	-$1.34
Diluted Shares (Avg)	40M	41M	N/A	19M	14M	9M	N/A	2M

Not reported in any period shown, so not listed: Income Tax.

SCNX Balance Sheet

SCNX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Total Assets	$84.2M-19.7%	$104.9M+736.6%	$12.5M+237.8%	$3.7M-35.7%	$5.8M-41.1%	$9.8M+75.8%	$5.6M+150.1%	$2.2M+260.8%	$617K+83.2%	$337K-83.4%	$2.0M+65.9%	$1.2M+202.6%	$404K
Current Assets	$7.9M+25.5%	$6.3M+129.0%	$2.8M+31.5%	$2.1M-52.1%	$4.4M-52.6%	$9.2M+142.5%	$3.8M+159.4%	$1.5M+141.3%	$607K+80.2%	$337K-35.7%	$524K-57.0%	$1.2M+208.2%	$395K
Cash & Equivalents	$6.7M+2062.3%	$308K+85245.2%	$361-100.0%	$1.1M-64.9%	$3.1M-47.2%	$5.9M+106.1%	$2.9M+230.2%	$870K+372.8%	$184K+1152.9%	$15K-81.4%	$79K-88.7%	$696K+725.2%	$84K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$213K	N/A	$968-98.5%	$66K+16.4%	$56K-95.5%	$1.3M+2115.9%	$57K-29.0%	$80K	N/A	N/A	$285K+513.2%	$46K+7.0%	$43K
Accounts Receivable	$731K+6485.0%	$11K+30.8%	$8K-98.7%	$630K-35.7%	$979K+21.6%	$805K+1.6%	$792K+82.7%	$434K+35.7%	$319K+6.8%	$299K-15.7%	$355K+1.6%	$349K+229.7%	$106K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	$21.4M	N/A	$0	$0	N/A	$726K0.0%	$726K	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$14.1M-45.5%	$25.8M+115.0%	$12.0M+256.1%	$3.4M+68.7%	$2.0M+79.2%	$1.1M-22.2%	$1.4M+3.5%	$1.4M+48.8%	$929K-37.4%	$1.5M-15.6%	$1.8M+218.0%	$554K+102.8%	$273K
Current Liabilities	$2.7M-65.4%	$7.9M-31.6%	$11.6M+438.3%	$2.1M+131.8%	$926K+9.9%	$842K+61.7%	$521K-39.5%	$860K+63.8%	$525K-64.4%	$1.5M-16.2%	$1.8M+218.0%	$554K+102.8%	$273K
Non-Current Liabilities	$11.3M-36.7%	$17.9M+4016.7%	$434K-64.4%	$1.2M+14.1%	$1.1M+294.4%	$271K-70.2%	$910K+74.2%	$523K+29.3%	$404K+3716.5%	$11K	$0	$0	$0
Long-Term Debt	N/A	$2.9M	N/A	N/A	N/A	N/A	$225K-56.9%	$522K-21.7%	$667K	N/A	N/A	N/A	N/A
Total Equity	$70.1M-11.3%	$79.1M+14479.5%	$542K-28.9%	$763K-79.8%	$3.8M-56.6%	$8.7M+109.6%	$4.1M+390.2%	$845K+370.8%	-$312K+72.8%	-$1.1M-530.0%	$267K-60.1%	$668K+410.8%	$131K
Retained Earnings	-$80.6M-106.3%	-$39.0M-17.4%	-$33.2M-68.6%	-$19.7M-21.4%	-$16.2M-48.6%	-$10.9M-30.2%	-$8.4M-3.5%	-$8.1M+0.1%	-$8.1M+3.4%	-$8.4M-48.9%	-$5.6M-24.7%	-$4.5M-79.9%	-$2.5M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$87.7M+4.2%	$80.7M-4.2%	$84.2M-19.7%	$104.8M+11.2%	$84.2M+466.9%	$84.2M-19.7%	$104.9M+736.6%	$94.3M+335.3%
Current Assets	$9.2M+974.2%	$4.8M-39.0%	$7.9M+25.5%	$1.4M-80.4%	$857K-92.9%	$7.8M-44.2%	$6.3M+129.0%	$7.3M+30.8%
Cash & Equivalents	$8.2M+53100.8%	$3.5M+72.8%	$6.7M+2062.3%	$356K-38.6%	$15K-99.8%	$2.0M-41.4%	$308K+85245.2%	$579K+1601.7%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$203K	$211K	$213K	$235K+2874.6%	N/A	N/A	N/A	$8K-99.7%
Accounts Receivable	$385K	$723K+19250.4%	$731K+6485.0%	$590K+5557.2%	N/A	$4K-46.2%	$11K+30.8%	$10K-98.8%
Long-Term Investments	$0	$0	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0	$2.5M
Goodwill	N/A	N/A	N/A	$21.4M+172.3%	$21.4M	$21.4M	$21.4M	$7.8M+53.0%
Total Liabilities	$23.6M-10.6%	$13.8M+359.0%	$14.1M-45.5%	$22.2M+142.8%	$26.4M+763.0%	$3.0M-96.7%	$25.8M+115.0%	$9.1M-9.6%
Current Liabilities	$3.0M-60.6%	$2.8M	$2.7M-65.4%	$7.4M+35.8%	$7.7M+164.9%	N/A	$7.9M-31.6%	$5.4M-40.5%
Non-Current Liabilities	$20.6M+9.9%	$11.0M	$11.3M-36.7%	$14.8M+298.7%	$18.7M+11543.9%	N/A	$17.9M+4016.7%	$3.7M+270.7%
Long-Term Debt	N/A	N/A	N/A	$2.0M	$3.6M	$3.1M	$2.9M	N/A
Total Equity	$64.1M-17.7%	$66.8M-17.7%	$70.1M-11.3%	$82.7M-2.9%	$77.9M+560.6%	$81.2M+496.0%	$79.1M+14479.5%	$85.1M+636.5%
Retained Earnings	-$86.8M-77.7%	-$84.0M-99.4%	-$80.6M-106.3%	-$52.4M-64.5%	-$48.8M-84.2%	-$42.1M-70.7%	-$39.0M-17.4%	-$31.9M-48.1%

SCNX Cash Flow Statement

SCNX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Cash Flow	-$14.4M	-$13.4M+6.2%	-$14.3M-541.1%	-$2.2M-45.8%	-$1.5M+40.5%	-$2.6M-15.9%	-$2.2M-1662.2%	$142K-48.1%	$273K+59.3%	$172K+134.1%	-$504K-657.1%	$90K+108.5%	-$1.1M-26.0%	-$845K
Depreciation & Amortization	N/A	$492K+24489.0%	$2K-99.8%	$834K+1348.6%	$58K+683.4%	$7K+33.7%	$6K+10.0%	$5K	N/A	$13K	$0-100.0%	$4K-20.8%	$5K+20.4%	$4K
Stock-Based Compensation	N/A	$2.1M+7986.7%	$26K-14.0%	$30K-62.4%	$79K+23.4%	$64K-85.7%	$448K+154.2%	$176K	N/A	N/A	N/A	$0-100.0%	$576K	N/A
Capital Expenditures	N/A	N/A	$12K	N/A	N/A	$23K-39.8%	$38K	N/A	N/A	N/A	N/A	N/A	N/A	$11K
Free Cash Flow	N/A	N/A	-$14.3M	N/A	N/A	-$2.6M-14.9%	-$2.3M	N/A	N/A	N/A	N/A	N/A	N/A	-$856K
Investing Cash Flow	N/A	N/A	$27.6M+10093.1%	-$276K+35.6%	-$428K-1793.5%	-$23K+39.8%	-$38K+88.7%	-$332K-25.2%	-$265K	$0+100.0%	-$78K	N/A	N/A	$11K
Financing Cash Flow	$25.6M	$19.7M+252.0%	-$13.0M-1023.0%	$1.4M+4098.6%	-$35K+83.1%	-$208K-103.9%	$5.3M+141.7%	$2.2M+223.6%	$678K+27924.9%	-$2K	N/A	$1.4M-19.5%	$1.7M+80.0%	$937K
Dividends Paid	N/A	N/A	$14.9M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$3.1M-54.0%	-$2.9M+1.3%	-$5.2M-77.9%	-$3.2M+40.4%	-$2.0M-148.2%	-$3.0M+71.0%	-$2.9M-185.5%	-$5.4M-793.4%
Depreciation & Amortization	$462K+92214.2%	$454K+90769.2%	N/A	$500-50.0%	$5000.0%	$5000.0%	$0-100.0%	$1K-64.6%
Stock-Based Compensation	N/A	$102K+23314.2%	N/A	N/A	N/A	$437-98.2%	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$2.9M	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	$0+100.0%	$121K+158.4%
Financing Cash Flow	$10.8M	-$200K-104.3%	$11.5M+311.5%	$3.6M+289.7%	$0	$4.7M+133.8%	$2.8M+108.9%	-$1.9M-1730.0%
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	$0	$2.2M

Not reported in any period shown, so not listed: Share Buybacks.

SCNX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SCNX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Gross Margin	76.8%+72.4pp	4.4%+0.8pp	3.6%-50.2pp	53.8%+5.9pp	48.0%+14.7pp	33.3%-32.2pp	65.5%-22.8pp	88.3%-11.7pp	100.0%0.0pp	100.0%+6.5pp	93.5%+22.9pp	70.6%+69.3pp	1.2%
Operating Margin	-9867.9%	-10758.7%	-322.4%	-28.4%+25.1pp	-53.5%-38.9pp	-14.6%-16.3pp	1.7%+4.0pp	-2.3%-15.8pp	13.5%+54.1pp	-40.6%-35.9pp	-4.7%+91.0pp	-95.7%	-218.0%
Net Margin	-9618.0%	6634.7%	-1308.3%	-33.9%+19.9pp	-53.8%-38.9pp	-14.8%-11.0pp	-3.8%-4.1pp	0.2%-9.6pp	9.9%	-111.2%	-38.4%	-134.5%	-218.8%
Return on Equity	-59.2%-70.7pp	11.5%+3301.5pp	-3290.0%-2835.1pp	-455.0%-314.0pp	-141.0%-111.8pp	-29.2%-22.4pp	-6.9%-7.9pp	1.1%	N/A	N/A	-418.4%-117.4pp	-301.0%+1297.0pp	-1598.0%
Return on Assets	-49.3%-58.0pp	8.6%+151.0pp	-142.4%-48.8pp	-93.6%-1.4pp	-92.2%-66.3pp	-25.9%-20.8pp	-5.1%-5.5pp	0.4%-46.4pp	46.8%+865.5pp	-818.7%-763.6pp	-55.1%+109.5pp	-164.6%+353.2pp	-517.8%
Current Ratio	2.89+2.1x	0.80+0.6x	0.24-0.7x	0.97-3.7x	4.72-6.2x	10.95+3.6x	7.30+5.6x	1.70+0.5x	1.16+0.9x	0.23-0.1x	0.30-1.9x	2.20+0.8x	1.45
Debt-to-Equity	0.20+0.2x	0.04-22.1x	22.11+17.7x	4.41+3.9x	0.53+0.4x	0.13+0.1x	0.05-0.6x	0.62	N/A	N/A	6.59+5.8x	0.83-1.3x	2.09
Asset Turnover	0.010.0x	0.00-0.1x	0.11-2.7x	2.76+1.0x	1.720.0x	1.75+0.4x	1.33-0.4x	1.72-3.0x	4.75-2.6x	7.36+5.9x	1.44+0.2x	1.22-1.1x	2.37
FCF Margin	N/A	-10448.6%	N/A	N/A	-26.2%-13.0pp	-13.2%	N/A	N/A	N/A	N/A	N/A	N/A	-89.5%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	97.7%	95.6%+89.0pp	N/A	97.4%+91.4pp	N/A	6.6%	N/A	6.0%-4.1pp
Operating Margin	-785.6%	-6230.8%	N/A	-739.1%	N/A	-34814.9%	N/A	-5392.8%
Net Margin	-821.3%	-6040.4%	N/A	-611.4%	N/A	-29869.3%	N/A	-4908.3%
Return on Equity	-4.4%+4.2pp	-5.1%-1.3pp	N/A	-4.4%-0.6pp	-8.6%+6.9pp	-3.8%-159.8pp	N/A	-3.7%+26.8pp
Return on Assets	-3.2%+4.8pp	-4.2%-0.6pp	N/A	-3.4%-0.1pp	-8.0%+4.4pp	-3.6%-23.9pp	N/A	-3.4%+12.9pp
Current Ratio	3.04+2.9x	1.70	2.89+2.1x	0.19-1.1x	0.11-4.1x	N/A	0.80+0.6x	1.34+0.7x
Debt-to-Equity	0.37+0.3x	0.21+0.2x	0.20+0.2x	0.02-0.1x	0.05-0.2x	0.04-6.7x	0.04-22.1x	0.11-0.8x
Asset Turnover	0.00	0.000.0x	N/A	0.010.0x	N/A	0.00	N/A	0.000.0x

Not reported in any period shown, so not listed: FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Scienture Holdings, Inc SCNX	FY2025	$432K	-$41.5M	N/A	$15.2M	—
Cellyan Biotechnology Co Ltd HKPD	FY2025	$20.3M	-$27K	-0.1%	$7.4M	49/100
Petmed Express Inc PETS	FY2026	$179.0M	-$57.3M	-32.0%	$40.4M	26/100
Wellgistics Health Inc. WGRX	FY2025	$23.3M	-$101.3M	N/A	$8.8M	25/100

Where Scienture Holdings, Inc Ranks

Frequently Asked Questions

What is Scienture Holdings, Inc's annual revenue?

Scienture Holdings, Inc (SCNX) reported $432K in total revenue for fiscal year 2025. This represents a 215.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Scienture Holdings, Inc's revenue growing?

Scienture Holdings, Inc (SCNX) revenue grew by 215.9% year-over-year, from $137K to $432K in fiscal year 2025.

Is Scienture Holdings, Inc profitable?

No, Scienture Holdings, Inc (SCNX) reported a net income of -$41.5M in fiscal year 2025.

What is Scienture Holdings, Inc's EBITDA?

Scienture Holdings, Inc (SCNX) had EBITDA of -$42.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Scienture Holdings, Inc's gross margin?

Scienture Holdings, Inc (SCNX) had a gross margin of 76.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Scienture Holdings, Inc's return on equity (ROE)?

Scienture Holdings, Inc (SCNX) has a return on equity of -59.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Scienture Holdings, Inc's operating cash flow?

Scienture Holdings, Inc (SCNX) recorded an outflow of $13.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Scienture Holdings, Inc's total assets?

Scienture Holdings, Inc (SCNX) had $84.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Scienture Holdings, Inc spend on research and development?

Scienture Holdings, Inc (SCNX) invested $2.0M in research and development during fiscal year 2025.

How many shares does Scienture Holdings, Inc have outstanding?

Scienture Holdings, Inc (SCNX) had 41M shares outstanding as of fiscal year 2025.

What is Scienture Holdings, Inc's current ratio?

Scienture Holdings, Inc (SCNX) had a current ratio of 2.89 as of fiscal year 2025, which is generally considered healthy.

What is Scienture Holdings, Inc's debt-to-equity ratio?

Scienture Holdings, Inc (SCNX) had a debt-to-equity ratio of 0.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Scienture Holdings, Inc's return on assets (ROA)?

Scienture Holdings, Inc (SCNX) had a return on assets of -49.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Scienture Holdings, Inc's P/E ratio?

Scienture Holdings, Inc (SCNX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $15.2M as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Scienture Holdings, Inc's price-to-sales ratio?

Scienture Holdings, Inc (SCNX) trades at 35.2x sales, its market capitalization divided by revenue of $432K revenue, FY2025. The market capitalization is $15.2M as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Scienture Holdings, Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Scienture Holdings, Inc (SCNX) held $6.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $13.4M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Scienture Holdings, Inc's Altman Z-Score?

Scienture Holdings, Inc (SCNX) has an Altman Z-Score of -2.28, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Scienture Holdings, Inc's Piotroski F-Score?

Scienture Holdings, Inc (SCNX) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Scienture Holdings, Inc's earnings high quality?

Scienture Holdings, Inc (SCNX) reported a net loss of $41.5M while operations used $13.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Scienture Holdings, Inc cover its interest payments?

Scienture Holdings, Inc (SCNX) reported an operating loss of $42.6M against $4.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.